Skip to main content

Table 2 In vivo anti-malarial activity against Plasmodium berghei

From: New endoperoxides highly active in vivo and in vitro against artemisinin-resistant Plasmodium falciparum

Compound

Dose (mg/kg/day)

Mean parasitaemia ± SD (% inhibition of parasite growth)b

Day 5

Day 7

Day 10

Controla

 

1.51 ± 0.22

3.58 ± 0.81

5.65 ± 0.43

LC92

50

0.02 ± 0.05 (98.34)

0.46 ± 0.60 (86.99)

0.77 ± 0.26 (86.27)

LC129

50

0.19 ± 0.12 (87.60)

1.76 ± 1.36 (50.69)

1.32 ± 1.24 (76.67)

LC130

50

0 (100)

1.4 ± 0.94 (60.83)

1.32 ± 0.24 (76.67)

LC131

50

0 (100)

0 (100)

0 (100)

LC132

50

0 (100)

0 (100)

0.31 ± 0.10 (94.46)

LC136

50

0 (100)

0 (100)

0 (100)

MIS13

50

0.11 ± 0.19 (92.56)

0.05 ± 0.10 (98.60)

0 (100)

LC163

50

0 (100)

0 (100)

0.2 ± 0.13 (96.46)

  1. SD standard deviation
  2. aControl: treated with PBS 1% DMSO
  3. bParasitaemia reduction compared to untreated control group